MEwens
Deconstructing the deal’s CVR; solving Genzyme’s manufacturing problems; avoiding the pitfalls of pharma-biotech deals; Viehbacher’s legacy.
Read more this great post here
Continued Read ...
MEwens
For the French pharma company, the deal’s immediate benefits may be more important.
Read more this great post here
Continued Read ...
Katherine Hobson
Financial terms of the alliance weren’t disclosed.
Read more this great post here
Continued Read ...
MEwens
It’s not yet clear whether generic versions of large-molecule biologic drugs will have to undergo separate trials.
Read more this great post here
Continued Read ...
MEwens
Wall Street Journal health blogger Katherine Hobson will take questions from readers in a live chat on Monday, Nov. 1 about the TEDMED conference in San Diego. Ask your questions now.
Read more this great post here
Continued Read ...
MEwens
Wall Street Journal health blogger Katherine Hobson will take questions from readers in a live chat on Monday, Nov. 1 about the TEDMED conference in San Diego. Ask your questions now.
Read more this great post here
Continued Read ...
Katherine Hobson
Viehbacher hasn’t publicly mentioned whether, or by how much, he’d be willing to up the ante.
Read more this great post here
Continued Read ...
Katherine Hobson
Also: the biotech sector gets smaller; a study eases fears of Plavix-heartburn drug interaction; Calif. middle-schoolers will get whooping cough booster.
Read more this great post here
Continued Read ...
Thomas M. Burton
Also: California doctors steamed over insurer’s quality ratings; Obama administration warns insurers; what will happen to brokers?
Read more this great post here
Continued Read ...
Katherine Hobson
In which the judge seeks an answer for an existential pharmaceutical question and praises submissions from AARP and Medco.
Read more this great post here
Continued Read ...
Next Page »
|
|
|
